GLPwatch
Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.
JAMA · 2026
Last updated 2026-07-12| Journal | JAMA, 2026 |
|---|---|
| Citations | 0 |
| Molecules | orforglipron, mazdutide |
Full record and abstract on PubMed 42251768 ↗
Related research
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.